Savara to Present at the Jefferies London Healthcare Conference

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the Jefferies London Healthcare Conference being held November 16-19, 2021.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Wednesday, November 10, 2021
Information
Tags: 
Biotechnology, Pharmaceutical, Health, Clinical Trials, Inc., Pulmonology, Investor, Savara, Granulocyte-macrophage colony-stimulating factor, APAP, Degenerative disease, Twitter, Conference, LinkedIn, GM-CSF, Pharmaceutical industry
Geotags: 
Europe, United States, United Kingdom, Texas
⚠ generated by AI ↴
Organisation: 
SAVARA
Summary
Key Points: 
  • Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the Jefferies London Healthcare Conference being held November 16-19, 2021.
  • A pre-recorded, on-demand webcast of Savaras presentation will be available on the conference website beginning Thursday, November 18 at 3:00 am ET through Friday, November 19 at 12:00 pm ET.
  • Additionally, a replay of the presentation will be available on the Investors page of Savaras website at www.savarapharma.com/investors/events-presentations/ for 90 days following the event.
  • Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases.


Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the Jefferies London Healthcare Conference being held November 16-19, 2021.

A pre-recorded, on-demand webcast of Savara’s presentation will be available on the conference website beginning Thursday, November 18 at 3:00 am ET through Friday, November 19 at 12:00 pm ET. Additionally, a replay of the presentation will be available on the Investors page of Savara’s website at www.savarapharma.com/investors/events-presentations/ for 90 days following the event.

About Savara

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization.

More information can be found at www.savarapharma.com. (Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).

Copyright: 
Copyright Business Wire 2021